| Texto completo | |
| Autor(es): |
Macedo, Luiza de Oliveira
;
da Silva, Rosana Pereira
;
de Jesus, Daniel Felipe Freitas
;
Bragard, Andre Sampaio
;
de Araujo, Gabriel Lima Barros
;
Ferraz, Humberto Gomes
;
Ishida, Kelly
;
Bou-Chacra, Nadia Araci
Número total de Autores: 8
|
| Tipo de documento: | Artigo Científico |
| Fonte: | International Journal of Pharmaceutics; v. 679, p. 15-pg., 2025-06-30. |
| Resumo | |
This study aimed to develop drug nanocrystals to enhance the aqueous solubility of firocoxib, an anti-inflammatory drug used in the treatment of pain in the veterinary field. Different non-ionic stabilizers were evaluated to obtain firocoxib nanocrystals with reduced particle size, increased saturation solubility, and adequate storage stability. Optimization using the Box-Behnken design resulted in nanocrystals with a particle size of < 200 nm. In vitro dissolution testing demonstrated a 1.5-fold increase in drug dissolution compared to the pure drug. Safety assessment in Galleria mellonella L. larvae revealed any acute toxicity below a dosage of 50 times. In the pharmacokinetic study in beagle dogs, the nanocrystals improved C-max in 2x compared to commercial product. Physicochemical stability was maintained over 12 months, with reduced variability in particle size and a PdI < 0.3. Additionally, an exploratory scale-up study successfully produced 3000 g of firocoxib nanocrystals with particle size < 400 nm. These findings suggest that firocoxib nanocrystals have the potential to enhance drug absorption and enabling faster symptom relief from inflammation and pain in dogs. (AU) | |
| Processo FAPESP: | 21/12869-8 - Nanocristais de firocoxibe para o manejo da osteoartrite veterinária: desenvolvimento, caracterização físico-química e avaliação da segurança in vitro |
| Beneficiário: | Isabela Fernandes de Oliveira |
| Modalidade de apoio: | Auxílio à Pesquisa - Pesquisa Inovativa em Pequenas Empresas - PIPE |